OncoDxRx

OncoDxRx is a pioneering medical and diagnostic laboratory dedicated to revolutionizing patient care through innovative liquid biopsy solutions. Located in Los Angeles, California, OncoDxRx focuses on developing and providing exclusive, transformative diagnostics and therapeutics to address significant unmet needs in the genetic healthcare market. The company is committed to delivering patient-centered solutions driven by cutting-edge technology. OncoDxRx’s primary address is 150 N Santa Anita Ave, Los Angeles, California 91006, US.

OncoDxRx's pipeline includes early cancer detection, treatment selection, monitoring recurrence, and therapeutic development. The company's flagship assay, PGA (patient-derived gene expression-informed anti-cancer drug efficacy), offers comprehensive anti-cancer drug efficacy data within five days, significantly improving clinical outcomes for cancer patients. OncoDxRx's research has also identified ten CpG methylation biomarkers for early cancer detection, achieving an AUC of 0.895 across 14 cancer types.

Driven by innovation and a commitment to improving patient outcomes, OncoDxRx continues to advance its pipeline of unique assays for minimal residual disease (MRD), DNA repair activity (HRR and/or MMR), tissue-of-origin identification, and cancer drug discovery. OncoDxRx is dedicated to making a significant impact on healthcare through its advanced diagnostic and therapeutic solutions. We invite the manager of OncoDxRx to create a customized and exclusive company showcase and product listing on our platform to further highlight these advancements.